Insulet (PODD) Faces Class Action Deadline, Is It A Bargain?

Insulet (PODD) is back in focus after several law firms reminded investors of an August 31, 2026 securities class action deadline related to alleged misstatements about manufacturing controls and Omnipod device safety.

See our latest analysis for Insulet.

Insulet’s share price closed at US$146.87 on 19 August 2026, with a 1 day share price return that declined 3.06% and a 30 day share price return that declined 10.29%, while the 1 year total shareholder return declined 55.20%. This points to weakening momentum as legal and product safety headlines remain in focus.

If this kind of legal driven volatility has you looking wider, it could be a good moment to see what else the market is pricing into healthcare focused AI opportunities using the 40 healthcare AI stocks

After Insulet’s share price slide and legal overhang, some investors might see a reset, while others prefer to wait for clearer skies. The next step is to assess what the current valuation implies about the price investors are being asked to pay.

Most Popular Narrative: 37.6% Undervalued

On the most followed narrative, Insulet’s fair value of $235.54 sits well above the last close at $146.87, which puts a spotlight on the growth and profitability assumptions behind that gap.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Read the complete narrative.

Want to see what underpins that valuation spread between $146.87 and $235.54? The narrative leans on sustained revenue growth, rising margins, and a richer earnings profile built into a discounted cash flow style framework that uses a specific long term growth and discount rate mix.

Result: Fair Value of $235.54 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the Insulet narrative still hinges on resolving manufacturing quality issues, as well as managing competitive and regulatory pressure that could challenge Omnipod driven growth assumptions.

Find out about the key risks to this Insulet narrative.

Next Steps

With sentiment around Insulet still divided, it makes sense to check the underlying metrics yourself and move quickly to form your own view. To see what investors are finding encouraging right now, start with the 4 key rewards

Looking for more investment ideas beyond Insulet?

Broaden your watchlist now and give yourself more options. Fresh ideas often emerge where fewer people are looking, so do not miss what could matter next.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com